Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
Celcuity (CELC) Stock Price & Analysis
217 Followers
CELC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.39 - $22.19
Previous Close$16.64
Volume336.10K
Average Volume (3M)272.55K
Market Cap
$584.08M
Enterprise Value$440.95M
Total Cash (Recent Filing)$180.58M
Total Debt (Recent Filing)$37.45M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 08, 2024EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.79
Shares Outstanding31,230,085
10 Day Avg. Volume289,662
30 Day Avg. Volume272,547
Standard Deviation0.26
R-Squared0.03
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.59
Forecast
1Y Price Target
$30.00Price Target Upside85.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Celcuity News
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial results from the Phase I study of gedatolisib plus Nubeqa in metastatic castration-resistant prostate cancer post-androgen receptor inhibitor are promising.
Financial PerformanceCelcuity is financing the new study via approximately $122 million in proceeds from amending its loan agreement and completion of a public financing.
Study EnrollmentEnrollment in the pivotal VIKTORIA-1 study is progressing on-time, with more than 50% of wild-type patients enrolled by the end of the quarter.
Bears Say
Financial PerformanceThe company reported no revenues, and a net loss of $0.64 per diluted share.
Investor EngagementTo opt-out of future communications and updates on Celcuity, recipients are given instructions, suggesting a possibility for reduced future engagement.
Stock RatingMaintaining a Buy Rating and lowering the Target to $23 after adjusting for dilution.
---
Ownership Overview
13.25% Insiders
8.44% Mutual Funds
43.37% Other Institutional Investors
34.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $8.39 and its highest was $22.19 in the past 12 months.
What is Celcuity’s market cap?
Currently, no data Available
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is Aug 08, 2024 which is in 36 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on May 15, 2024. The company reported -$0.64 earnings per share for the quarter, beating the consensus estimate of -$0.696 by $0.056.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -$0.67.
How many shares outstanding does Celcuity have?
Celcuity has 35,101,086 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$0.64 in its last earnings report, beating expectations of -$0.696. Following the earnings report the stock price went up 2.496%.
Which hedge fund is a major shareholder of Celcuity?
Among the largest hedge funds holding Celcuity’s share is Perceptive Advisors LLC. It holds Celcuity’s shares valued at 51M.
---
Celcuity Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (85.30% Upside)
$30.00 (85.30% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $48.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.54%
12-Months-Change
Fundamentals
Return on Equity
-57.17%
Trailing 12-Months
Asset Growth
14.14%
Trailing 12-Months
Company Description
Celcuity
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded in January 2012 by Brian Sullivan and Lance Laing and is headquartered in Minneapolis, MN.
---
CELC Earnings Call
Q1 2024
0:00 / 0:00
---
CELC Stock 12 Month Forecast
Average Price Target
$30.00
▲(85.30% Upside)
Technical Analysis
Best Analysts Covering CELC
1 Year
---